Akili Interactive

Akili Interactive is a pioneering company in the field of digital medicine, creating game-based treatments to improve cognitive impairments. Their flagship product, EndeavorRx®, is the first FDA-authorized prescription video game treatment for children with ADHD and has also received CE Mark certification in Europe. EndeavorRx® utilizes proprietary technology to present specific sensory stimuli and simultaneous motor challenges targeting neural systems related to attentional control. Akili’s EndeavorOTC™ is another clinically proven game-based treatment designed to enhance attention and focus in adults with ADHD, available on the App Store® and Google Play.

Akili’s digital therapeutics are built on a robust technology platform grounded in extensive peer-reviewed research and have been studied in over 30 clinical trials. Their products, including the Selective Stimulus Management Engine (SSME™), Body Brain Trainer (BBT™), and Spatial Navigation (SNAV™) Engine, are engineered to deliver sensory and motor stimuli to selectively target and activate specific cognitive neural systems in the brain. These treatments are designed to be adaptive, automatically adjusting the “dose” to each person’s individual needs, and include second-by-second monitoring of progress for continuous assessment by doctors and caregivers.

Akili’s mission is to ignite new hope for those living with cognitive impairment by creating a new class of digital medicines that are fun and engaging, leveraging the engagement and rewards that make games compelling. Their digital treatments aim to be so captivating that patients forget they are taking medicine. Akili operates offices in Boston and the SF Bay Area, with a commitment to rigorous testing through extensive clinical studies, including prospective randomized, controlled trials, to ensure the efficacy and safety of their products.